Phacilitate Cell and Gene Therapy World 2018: Translating innovation to global success

Posted by Rob Jones on Jan 10, 2018 10:00:00 AM
Phacilitate 2018 Logo .png

As the past year has proven, the advancements in cell and gene therapy are increasing at a rapid pace and are transforming the way we think about medicine. Whether in research or in the clinic, scientific innovators are acutely aware that every moment counts when working with these valuable therapies. To facilitate knowledge sharing and collaboration, Thermo Fisher Scientific is proud to support Phacilitate Cell and Gene Therapy World 2018 as the Platinum Sponsor. 

We will showcase our comprehensive advanced therapy offering from booth #501, highlighting products and services that support the entirety of the workflow from discovery to cure.  We are also hosting and participating in several insightful sessions:

The BioProcess Hub

Are you concerned about the quality, scaling up/out, and standardization of your cell or gene therapy product? If so, join us for an illuminating journey through the BioProcess
Hub where our Thermo Fisher Scientific team will highlight the things you need to know about expansion media.

Gene Therapy Panel, January 24, 11:20AM, Jasmin

How to address viral and non-viral vector manufacturing capacity/supply shortfalls before they reach crisis point
Defining both the scale of the challenge and the strategic solutions available today and in the future

Featured panelists include:
- Dr. Bo Kara, Head Process Development, Cell & Gene Therapy Platform CMC - GlaxoSmithKline
- Dr. Richard Jude Samulski, Vice President, Gene Therapy - Bamboo Therapeutics, Inc., a wholly owned subsidiary of Pfizer Inc.
- Ryan Scanlon, Business Head, Viral Therapeutics, Lonza
- Dr. Nicole Faust, Chief Scientific Officer, CEVEC Pharmaceuticals
- Dr. Klaus Kühlcke, Managing Director, EUFETS GmbH
- Dr. Xavier de Mollerat du Jeu, Director R&D, Life Science Group, Thermo Fisher Scientific

The Supply Chain & Logistics Hub

As the commercialization race heats up, many cell and gene therapy developers are concerned with the supply chain and logistics scale-up challenges they will face when their product becomes commercial. Effective management of the advanced therapy supply chain is a complex challenge, but also critical to developing a successful commercial model. The Supply Chain and Logistics Hub at Cell and Gene Therapy World 2018 will take attendees on an interactive journey through each stage of the advanced therapy supply chain. From the Fisher BioServices booth, we will share some of the important factors for consideration when developing your commercialization strategy and provide a picture of what your commercial process could look like.

Moderated Panel, January 24, 4:00PM, Orchid CD

Supply Chain Scale-Up Strategies and Enabling Technologies to Minimize COGS
Sector leaders’ tips for designing and implementing efficient, scalable cell & gene supply chains

Moderated by Rob Jones, Director, Advanced Therapies, Fisher BioServices
Featured panelists include:
- Simon Ellison, Cell and Gene Therapy Service Director, World Courier
- Stefano Baila, Director of Operations & Business Development, Holding F.I.S.
- Luděk Sojka, Ph.D., Chief Operating Officer, Sotio

Thermo Fisher Scientific offers integrated, scalable, and custom solutions to accelerate advanced therapy development to the clinic and beyond. We encourage you to attend our panel sessions or swing by booth #501 to chat with our team of experts. In the meantime, if you're interested in learning more about cell therapy development strategies and the role of the cold chain, download our webinar Cell Therapy: Achieving Success on the Road to Commercialization.


View Webinar Recording